Alright, the tape is screaming one thing: this is a takeover story, not a trading story. 🎯 All the news is about Bausch Health's $63 million buyout of DURECT. The technicals? Practically irrelevant now. The stock's fate is tied to that deal closing. The "investigations" are just noise—standard M&A procedure. The Big Call? If you own it, **HOLD** and wait for the deal cash. If you don't, there's no play here unless you're betting the deal falls apart. It's all about the merger math now. #AcquisitionArbitrage

"Boom! DRRX just got scooped up by Bausch Health—acquisition fever is real! 🚀 The stock exploded from $0.55 to $1.92 in a day (RSI at 90—overbought alert!), but that volume spike (43M shares!) screams FOMO. Short-term? Might cool off. Long-term? Buy the dip if you believe in the liver-drug hype. Lawyers sniffing around the deal price, though… 🧐 #MergerMoonshot"